Non-small cell lung cancer and precision medicine a model for the incorporation of genomic features into clinical trial design

JAMA

Volumn 311, Issue 19, 2014, Pages 1975-1976

  Pasche, Boris ^a   Grant, Stefan C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Heerskink School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

AKT1 GENE; ALK GENE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; EGFR GENE; ENZYME ACTIVATION; ERBB2 GENE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC SCREENING; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; MEK1 GENE; MET GENE; NONHUMAN; ONCOGENE; ONCOGENE C ROS; ONCOGENE K RAS; ONCOGENE N RAS; PERSONALIZED MEDICINE; PIK3CA GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; STUDY DESIGN; SURVIVAL PREDICTION; SURVIVAL TIME;

ADENOCARCINOMA; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY;

EID: 84900834948     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3742     Document Type: Editorial

References (16)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. BMJ. 1995;311(7010):899-909.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346(2):92-98. (Pubitemid 34438899)
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355(24):2542- 2550. (Pubitemid 44917502)
5. Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012;307(15):1593-1601.
6. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53(10)(suppl):2379-2385. (Pubitemid 23156828)
7. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA. 2003;290(16):2149-2158. (Pubitemid 37432975)
8. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer. Science. 2004;304(5676):1497-1500.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. (Pubitemid 38637993)
10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306-13311. (Pubitemid 39209661)
11. Rosell R, Carcereny E, Gervais R, et al. Erlotinib vs standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC). Lancet Oncol. 2012;13(3):239-246.
12. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
13. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
14. Bergethon K, Shaw AT, Ignatius Ou S-H, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863-870.
15. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. doi:10.1001/jama.2014.3741.
16. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.